Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Disclosure of interest
- Why phenotype / subgroup? (1)
- Why phenotype / subgroup? (2)
- Phenotypes - one definition
- The "frequent exacerbator"?
- Eclipse study
- Exacerbations frequency and severity
- Multinomial regression
- Eclipse study virtue
- Stability of the exacerbator phenotype
- Frequent exacerbator clinical review
- There are no certainties
- COPD equation
- Venn diagram
- COPD - phenotypes
- First case of alpha1-antitrypsin deficiency 1963
- Severe emphysema X-ray image
- Severe emphysema CT scan
- MicroCT of the lung study
- Emphysema and small airways
- Patients with COPD and asthma
- Asthma and FEV1 decline
- Chronic bronchitis
- Mucus hypersecretion, and decline in FEV1
- Predictive value of chronic bronchitis
- COPD archetype
- Important phenotypes in COPD
- FEV1 decline, disease progression and severity
- COPD activity
- FEV1 decline by stage
- A biomarker for disease activity in COPD
- COPD lung function decline variety (1)
- COPD lung function decline variety (2)
- COPD biomarkers
- Novel COPD phenotypes
- How many phenotypes are there?
- Conclusions
Topics Covered
- COPD
- More than one disease
- Definition of phenotypes
- Consideration of subgroups of COPD
- Traditional subgroupings
- Recently defined subgroupings
- What is the future of COPD?
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Vestbo, J. (2012, July 31). Clinical phenotypes of COPD [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/NEKV8913.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Jørgen Vestbo has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.